B
Bull
Bull · 25%EVH
$10.23
Szenariopreis
$4.600
+0.010 (+0.22%)Zum Schluss
Loading chart…
- High
- 4.740
- Open
- 4.540
- VWAP
- 4.59
- Vol
- 2.21M
- Mkt Cap
- 2.30B
- Low
- 4.430
- Amount
- 10.16M
- EV/EBITDA, TTM
- -198,853.35
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
AI analysis of Evolent Health Inc (EVH)
holdEvolent Health Inc is currently priced at $4.60, which is below the average analyst price target of $6. This suggests potential upside of approximately 30.43%. However, the stock has a forward P/E ratio of 25.91, indicating that it may be overvalued relative to its earnings potential. The recent RSI of 49.75 suggests the stock is neither overbought nor oversold, indicating a neutral momentum. The main risk is the high net debt-to-EBITDA ratio of 7x, which could pressure the company to raise capital under unfavorable conditions.
Analyst Ratings (13)
+102.83% upside
Buy
13 Buy
0 Hold
0 Sell
Current: 4.60
Tief
5.00
Durchschnitt
9.33
Hoch
16.00
Citi
Buy
$6
2026-08-10
Citi
2026-08-10
Kursziel
$6
Buy
Canaccord
Buy
$6
2026-08-10
Canaccord
2026-08-10
Kursziel
$6
Buy
TD Cowen
Buy
$5
2026-07-28
TD Cowen
2026-07-28
Kursziel
$5
Buy
Citi
Neutral
—
2026-07-23
Citi
2026-07-23
Kursziel
—
Neutral
Canaccord
Buy
$7
2026-07-21
Canaccord
2026-07-21
Kursziel
$7
Buy
Bewertungskennzahlen
The current forward P/E ratio for Evolent Health Inc (EVH) is 25.91, compared to its 5-year average forward P/E of 76.18.
Alphio AI Price Scenarios for EVH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding EVH
Event-Zeitleiste
News
6.508-16Yahoo FinanceHealthcare Stock Investment Opportunities and Risks Analysis
2.008-13NASDAQ.COMEvolent Health (EVH) Q2 2026 Earnings Call Transcript
6.008-11CNBCLatest Rating Changes on Wall Street
9.508-06seekingalphaEvolent Health Q2 Earnings Exceed Expectations
2.007-31Yahoo FinanceAnalysis of Small-Cap Investment Opportunities
EVH FAQ — answered by Alphio AI
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner. It operates in the Healthcare sector (SERVICES-MANAGEMENT SERVICES industry).
Evolent Health Inc is currently priced at $4.60, which is below the average analyst price target of $6. This suggests potential upside of approximately 30.43%. However, the stock has a forward P/E ratio of 25.91, indicating that it may be overvalued relative to its earnings potential. The recent RSI of 49.75 suggests the stock is neither overbought nor oversold, indicating a neutral momentum. The main risk is the high net debt-to-EBITDA ratio of 7x, which could pressure the company to raise capital under unfavorable conditions.
13 analysts cover EVH: 13 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.33.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.